New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLiraglutide vs Livagen

Liraglutide vs Livagen

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide
Anti-Aging & Longevity
Livagen
Summary
Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
Half-Life
~13 hours (once-daily dosing)
Short (minutes); gene-regulatory effects are sustained
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
Start 0.6 mg, titrate to 3 mg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Promotes weight loss (5–10% average)
  • Reduces appetite and caloric intake
  • Improves blood glucose control (HbA1c reduction)
  • Reduces cardiovascular events in T2DM (LEADER trial)
  • Slows gastric emptying
  • FDA-approved for T2DM and chronic weight management
  • Cardioprotective effects shown in clinical trials
  • May improve fatty liver (NAFLD/NASH)
  • Supports hepatocyte regeneration and liver tissue repair
  • Normalizes liver cell protein synthesis
  • Immune modulation via thymic activity
  • Potential benefits in chronic hepatitis and liver aging
  • Anti-aging effects on hepatic tissue
  • May support liver recovery after toxic insult or alcohol damage
  • Complementary to NAD+ and glutathione in liver health protocols
Side Effects
  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • +5 more
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hepatotoxic effects reported at standard doses
Stacks With